Vertex Pharma stock: Citi keeps Buy rating at USD 585.00 target
Published on 10/23/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and results
- Citi maintained a Buy rating and set a USD 585.00 target on October 19, 2026.
- Second-quarter 2026 revenue reached USD 3.33 billion, up 12.00 percent year over year.
- Vertex Pharma stock costs EUR 468.68 at Lang & Schwarz on October 23, 2026 at 4:41 p.m. CEST.
- Vertex Pharmaceuticals is scheduled to report third-quarter 2026 results on November 2, 2026.
Vertex Pharma (ISIN US92532F1003) remains anchored by a USD 585.00 price target from Citi, while second-quarter 2026 revenue reached USD 3.33 billion, up 12.00 percent year over year. Markets Insider reported on October 19, 2026 that Citi maintained its Buy rating and set the target at USD 585.00. Vertex Pharma was trading at EUR 468.68 at Lang & Schwarz on October 23, 2026 at 4:41 p.m. CEST.
Revenue growth remains measurable
The latest reported quarter combined higher sales with a larger profit base. Yahoo Finance reported that second-quarter 2026 revenue rose to USD 3.33 billion from USD 2.96 billion in the prior-year quarter, while net income increased to USD 1.10 billion from USD 1.03 billion. The company also raised full-year 2026 revenue guidance to USD 13.10 billion to USD 13.20 billion.
Price position remains central
The Lang & Schwarz price was EUR 468.68 on October 23, 2026 at 4:41 p.m. CEST. The primary Nasdaq quote was USD 526.16 at 2:55 p.m. UTC, with a day range of USD 522.76 to USD 532.99 and a 52-week range of USD 403.16 to USD 560.25. The euro quotation converts to a level within that dollar range, supporting a consistent cross-market picture.
Valuation and upcoming date
Citi's USD 585.00 target lies 11.18 percent above the Nasdaq price of USD 526.16, using the October 23, 2026 quote as the comparison. The finance profile also places Vertex's market capitalization at USD 133.4 billion and its trailing P/E at 30.64 as of October 23, 2026.
ChickenStock identifies Vertex Pharmaceuticals as a NASDAQ-listed company under ticker VRTX and lists November 2, 2026 as the next earnings date. That report will provide the next direct test of the raised revenue outlook.
What the target means for valuation
The target leaves room above the current Nasdaq quotation, but the valuation already reflects a profitable growth profile. Vertex's second-quarter net margin was 33.00 percent, while the company continued to invest in pipeline programs and commercial launches.
Stock stays tied to the next report
For investors, the key contrast is clear: revenue growth remains double digit, while Citi's target sets a concrete valuation marker ahead of the November 2, 2026 results.
The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex Pharma at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 23, 2026, 4:41 p.m. CEST): EUR 468.68
- Market capitalization: USD 133.4 billion (as of October 23, 2026)
- 52-week range: USD 403.16-560.25 (as of October 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 2, 2026
Market context: Market report S&P 500.
